Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells

Leukemia

Volumn 30, Issue 1, 2016, Pages 104-111

  Fink, E E ^a   Mannava, S ^a   Bagati, A ^a   Bianchi Smiraglia, A ^a   Nair, J R ^a   Moparthy, K ^a   Lipchick, B C ^a   Drokov, M ^b   Utley, A ^a   Ross, J ^a   Mendeleeva, L P ^b   Savchenko, V G ^b   Lee, K P ^a   Nikiforov, M A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; PROTEASOME INHIBITOR; REACTIVE OXYGEN METABOLITE; THIOREDOXIN REDUCTASE; THIOREDOXIN REDUCTASE 2; TXNRD2 PROTEIN, HUMAN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; DETOXIFICATION; DRUG EFFICACY; ECTOPIC EXPRESSION; ENDOPLASMIC RETICULUM STRESS; FEMALE; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; MYELOMA CELL; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR VOLUME; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; APOPTOSIS; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BORTEZOMIB; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM STRESS; FEMALE; HUMANS; MICE; MULTIPLE MYELOMA; OXIDATIVE STRESS; PROTEASOME INHIBITORS; REACTIVE OXYGEN SPECIES; THIOREDOXIN REDUCTASE 2;

EID: 84953345297     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.190     Document Type: Article

References (41)

1. Anderson KC. Bortezomib therapy for myeloma. Curr Hematol Rep 2004; 3: 65.
2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
3. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
4. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009; 374: 324-339.
5. Venner CP, Connors JM, Sutherland HJ, Shepherd JD, Hamata L, Mourad YA et al. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (o 12 months). Leuk Lymphoma 2011; 52: 34-41.
6. Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD et al. U. S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma. Clin Cancer Res 2013; 19: 4559-4563.
7. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383-6391.
8. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110: 3281-3290.
9. Parlati F, Lee S, Aujay M, Levitsky K, Lorens J, Lu Y et al. Carfilzomib: a selective inhibitor of the chymotrypsin-like activity of the constitutive proteasome and immunoproteasome has anti-tumor activity on multiple myeloma, lymphoma, and leukemia cells with minimal effects on normal cells. Haematologica 2009; 94: 0373.
10. Obeng EA, Carlson LM, Gutman DM, Harrington Jr WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907-4916.
11. Tabas I, Ron D. Integrating the Mechanisms of Apoptosis Induced by Endoplasmic Reticulum Stress. Nat Cell Biol 2011; 13: 184-190.
12. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408: 239-247.
13. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic Oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004; 53: 209-219.
14. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent Oxidative stress in Cancer. FEBS Letters 1995; 358: 1-3.
15. Schumacker PT. Reactive Oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006; 10: 175-176.
16. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003; 278: 33714-33723.
17. Du ZX, Zhang HY, Meng X, Guan Y, Wang HQ. Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells. BMC Cancer 2009; 9: 56.
18. Weniger MA, Rizzatti EG, Perez-Galan P, Liu D, Wang Q, Munson PJ et al. Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma. Clin Cancer Res 2011; 17: 5102-5112.
19. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004; 24: 9695-9704.
20. Bhandary B, Marahatta A, Kim HR, Chae HJ. An involvement of oxidative stress in endoplasmic reticulum stress and its associated diseases. Int J Mol Sci 2012; 14: 434-456.
21. Yu C, Rahmani M, Dent P, Grant S. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res 2004; 295: 555-566.
22. Mannava S, Zhuang D, Nair JR, Bansal R, Wawrzyniak JA, Zucker SN et al. KLF9 is a novel transcriptional regulator of bortezomib-and LBH589-induced apoptosis in multiple myeloma cells. Blood 2012; 119: 1450-1458.
23. Zucker SN, Fink EE, Bagati A, Mannava S, Bianchi-Smiraglia A, Bogner PN et al. Nrf2 Amplifies Oxidative Stress via Induction of Klf9. Molecular Cell 2014; 53: 916-928.
24. Arnér ES. Focus on mammalian thioredoxin reductases-important selenoproteins with versatile functions. Biochim Biophys Acta 2009; 1790: 495-526.
25. Horstkotte J, Perisic T, Schneider M, Lange P, Schroeder M, Kiermayer C et al. Mitochondrial thioredoxin reductase is essential for early postischemic myocardial protection. Circulation 2011; 124: 2892-2902.
26. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 2012; 120: 3260-3270.
27. Gado K, Silvia S, Paloczi K. Mouse Plasmacytoma: an experimental model of human multiple myeloma. Haematologica 2001; 86: 227-236.
28. Arnér ESJ, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000; 267: 6102-6109.
29. Fernández Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari Jr AW et al. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 2005; 65: 6294-6304.
30. Minami T, Adachi M, Kawamura R. Sulindac Enhances the Proteasome Inhibitor Bortezomib-Mediated Oxidative Stress and Anticancer Activity. Clin Cancer Res 2005; 11: 5248-5256.
31. Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT et al. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 2006; 134: 145-156.
32. Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J et al. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood 2010; 115: 61-70.
33. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639-16647.
34. Philips R, Bibby M, Double J. A critical appraisal of the predictive value of in vitro chemosensitivity assays. J Natl Cancer Inst 1990; 82: 1457-1468.
35. Michaelis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A et al. Anticancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int. J. Oncol 2006; 28: 439-446.
36. Malhorta JD, Kaufman RJ. Endoplasmic Reticulum Stress and Oxidative Stress: A Vicious Cycle or a Double-Edged Sword Antioxid Redox Signal 2007; 9: 2277-2293.
37. Verfaillie T, Rubio N, Garg AD, Bultynck G, Rizzuto R, Decuypere JP et al. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROSbased ER stress. Cell Death Differ 2012; 19: 1880-1891.
38. Tagawa Y, Hiramatsu N, Kasai A, Hayakawa K, Okamura M, Yao J et al. Induction of apoptosis by cigarette smoke via ROS-dependent endoplasmic reticulum stress and CCAAT/enhancer-binding protein-homologous protein (CHOP). Free Radic Biol Med 2008; 45: 50-59.
39. Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): a potent pandeacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 2009; 5: 601-612.
40. Shenp P, Sun J, Xu G, Zhang L, Yang Z, Xia S et al. KLF9, a transcription factor induced in flutamide-caused cell apoptosis, inhibits AKT activation and suppresses tumor growth of prostate cancer cells. Prostate 2014; 74: 946-958.
41. Nakaya A, Sagawa M, Muto A, Uchida H, Ikeda Y, Kizaki M. The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-B activity. Leuk Res 2011; 35: 243-249.